Industry News (Clinical Trials)

Preliminary Results from Doxil Trial in KS Patients Presented

Published in Cancer Weekly, December 18th, 1995

Sequus Pharmaceuticals, Inc., Menlo Park, California, announced the presentation of a poster by Dr. Donald W. Northfelt at the American Society of Hematology meeting, held in Seattle, Washington, indicating that a new cancer drug, Doxil, showed promising results when compared to standard combination chemotherapy (Adriamycin, Bleomycin and Vincristine, or "ABV") in treating Kaposi's sarcoma (KS) in people with AIDS.

According to the poster presentation, responses were assessed by modified AIDS Clinical Trial Group (ACTG) criteria. A total of 258 patients were enrolled in the trial; of these, 239 patients (131 Doxil and 108 ABV) received more than two cycles of therapy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry